Carlos Graux

Clustering and Kernel Density Estimation for Assessment of Measurable Residual Disease by Flow Cytometry

Jean-Michel Dogné, Bernard Chatelain, François Mullier, 2020, Diagnostics.

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Bob Löwenberg, Carlos Graux, Nancy Boeckx, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytarabine dose for acute myeloid leukemia.

Augustin Ferrant, Bob Löwenberg, Alois Gratwohl, 2011, The New England journal of medicine.

The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial

Daniel Wolff, Steffen Fieuws, Carlos Graux, 2018, Haematologica.

Fusion of EML 1 to ABL 1 in T-cell acute lymphoblastic leukemia with cryptic t ( 9 ; 14 ) ( q 34 ; q 32 )

Peter Marynen, Jan Cools, Carlos Graux, 2005 .

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.

Bob Löwenberg, Jakob Passweg, Carlos Graux, 2012, Blood.

Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).

Peter Marynen, Jan Cools, Carlos Graux, 2005, Blood.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

Markus G. Manz, Bob Löwenberg, Carlos Graux, 2018, The New England journal of medicine.

Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia

Rob Pieters, Frank Speleman, Peter Marynen, 2007, Nature Genetics.